(S)-(−)-Propranolol hydrochloride
SIGMA/P8688 - ≥98% (TLC), powder
Synonym: (S)
CAS Number: 4199-10-4
Empirical Formula (Hill Notation): C16H21NO2 · HCl
Molecular Weight: 295.80
EC Number: 224-096-0
MDL Number: MFCD00064547
Linear Formula: C10H7OCH2CH(OH)CH2NHCH(CH3)2·HCl
Product Type: Chemical
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: P8688-100MG
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: P8688-500MG
| assay | ≥98% (TLC) |
| form | powder |
| InChI | 1S/C16H21NO2.ClH/c1-12(2) |
| InChI key | ZMRUPTIKESYGQW-UQKRIMTDSA |
| mp | 193-195 °C (lit.) |
| optical activity | [α]25/D −25.5°, c = 1.0 in ethanol(lit.) |
| originator | AstraZeneca |
| Quality Level | 200  |
| SMILES string | Cl[H].CC(C)NC[C@H](O)COc1 |
| solubility | 45% (w/v) aq 2-hydroxypropyl-β-cyclode |
| DMSO: <14.5 mg/mL | |
| ethanol: 10 mg/mL | |
| H2O: 50 mg/mL | |
| storage temp. | 2-8°C |
| Application: | (S)-(−)-Propranolol hydrochloride has been used: • as a non-selective β-blocker propranolol to inhibit the actions of epinephrine in mice • as a β1- and β2-aadrenergic receptor blocker in rat • as a medium supplement to investigate its effect on adipogenesis in hemangioma-derived stem cells (HemSC) |
| Biochem/physiol Actions: | (S)-(−)-Propranolol hydrochloride is biologically active enantiomer. It acts as β1 receptor antagonist in thalamocortical neurons. (S)-(−)-Propranolol hydrochloride elicits its inhibitory function on the β1 adrenoceptor in trigeminovascular pain pathway and serves as a preventive medicine in migraine. |
| Biochem/physiol Actions: | Active β-adrenoceptor blocking enantiomer, as measured by inhibition of isoprenaline-induced tachycardia; Propranolol is also non-specific 5-HT1A, 5-HT1B and 5-HT1C serotonin receptor antagonist. The stereoselective association of mianserin and propranolol with the 5HT1A, 5HT1B and 5HT1C sites may prove useful in the characterization of these sites |
| Features and Benefits: | This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by AstraZeneca . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| General description: | With heat. Aqueous solutions are most stable at pH 3.0 and decompose rapidly at basic pH. Decomposition is accompanied by discoloration of the solution. |
| Packaging: | 100, 500 mg in glass bottle |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 + H312 + H332 |
| Precautionary statements | P261 - P264 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312 |
| Hazard Codes | Xn |
| Risk Statements | 20/21/22 |
| Safety Statements | 36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (TLC) |
| mp | 193-195 °C (lit.) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |